TY - JOUR
T1 - Treatment and outcomes in children with multidrug-resistant tuberculosis
T2 - A systematic review and individual patient data meta-analysis
AU - Collaborative Grp Meta-analysis
AU - Harausz, Elizabeth P.
AU - Garcia-Prats, Anthony J.
AU - Law, Stephanie
AU - Schaaf, H. Simon
AU - Kredo, Tamara
AU - Seddon, James A.
AU - Menzies, Dick
AU - Turkova, Anna
AU - Achar, Jay
AU - Amanullah, Farhana
AU - Barry, Pennan
AU - Becerra, Mercedes
AU - Chan, Edward D.
AU - Chan, Pei Chun
AU - Chiotan, Domnica Ioana
AU - Crossa, Aldo
AU - Drobac, Peter C.
AU - Fairlie, Lee
AU - Falzon, Dennis
AU - Flood, Jennifer
AU - Gegia, Medea
AU - Hicks, Robert M.
AU - Isaakidis, Petros
AU - Kadri, S. M.
AU - Kampmann, Beate
AU - Madhi, Shabir A.
AU - Marais, Else
AU - Mariandyshev, Andrei
AU - Mendez-Echevarria, Ana
AU - Moore, Brittany Kathryn
AU - Nargiza, Parpieva
AU - Ozere, Iveta
AU - Padayatchi, Nesri
AU - Saleem-ur-Rehman, null
AU - Rybak, Natasha
AU - Santiago-Garcia, Begona
AU - Shah, N. Sarita
AU - Sharma, Sangeeta
AU - Shim, Tae Sun
AU - Skrahina, Alena
AU - Soriano-Arandes, Antoni
AU - van den Boom, Martin
AU - van der Werf, Marieke J.
AU - van der Werf, Tjip S.
AU - Williams, Bhanu
AU - Yablokova, Elena
AU - Yim, Jae-Joon
AU - Furin, Jennifer
AU - Hesseling, Anneke C.
PY - 2018/7/11
Y1 - 2018/7/11
N2 - BackgroundAn estimated 32,000 children develop multidrug-resistant tuberculosis (MDR-TB; Mycobacterium tuberculosis resistant to isoniazid and rifampin) each year. Little is known about the optimal treatment for these children.Methods and findingsTo inform the pediatric aspects of the revised World Health Organization (WHO) MDR-TB treatment guidelines, we performed a systematic review and individual patient data (IPD) meta-analysis, describing treatment outcomes in children treated for MDR-TB. To identify eligible reports we searched PubMed, LILACS, Embase, The Cochrane Library, PsychINFO, and BioMedCentral databases through 1 October 2014. To identify unpublished data, we reviewed conference abstracts, contacted experts in the field, and requested data through other routes, including at national and international conferences and through organizations working in pediatric MDR-TB. A cohort was eligible for inclusion if it included a minimum of three children (agedConclusionsThis study suggests that children respond favorably to MDR-TB treatment. The low success rate in children infected with HIV who did not receive ART during their MDR-TB treatment highlights the need for ART in these children. Our findings of individual drug effects on treatment outcome should be further evaluated.
AB - BackgroundAn estimated 32,000 children develop multidrug-resistant tuberculosis (MDR-TB; Mycobacterium tuberculosis resistant to isoniazid and rifampin) each year. Little is known about the optimal treatment for these children.Methods and findingsTo inform the pediatric aspects of the revised World Health Organization (WHO) MDR-TB treatment guidelines, we performed a systematic review and individual patient data (IPD) meta-analysis, describing treatment outcomes in children treated for MDR-TB. To identify eligible reports we searched PubMed, LILACS, Embase, The Cochrane Library, PsychINFO, and BioMedCentral databases through 1 October 2014. To identify unpublished data, we reviewed conference abstracts, contacted experts in the field, and requested data through other routes, including at national and international conferences and through organizations working in pediatric MDR-TB. A cohort was eligible for inclusion if it included a minimum of three children (agedConclusionsThis study suggests that children respond favorably to MDR-TB treatment. The low success rate in children infected with HIV who did not receive ART during their MDR-TB treatment highlights the need for ART in these children. Our findings of individual drug effects on treatment outcome should be further evaluated.
KW - INTRATHORACIC TUBERCULOSIS
KW - PULMONARY TUBERCULOSIS
KW - ANTIRETROVIRAL THERAPY
KW - INFECTED CHILDREN
KW - YOUNG-CHILDREN
KW - SOUTH-AFRICA
KW - DISEASE
KW - MEDICATIONS
KW - MANAGEMENT
KW - INITIATION
U2 - 10.1371/journal.pmed.1002591
DO - 10.1371/journal.pmed.1002591
M3 - Article
VL - 15
JO - PLOS MEDICINE
JF - PLOS MEDICINE
SN - 1549-1277
IS - 7
M1 - 1002591
ER -